Scientists find molecular trail that helps melanoma spread
Cancer Research UK scientists at the Beatson Institute at the University of Glasgow and BBSRC-funded Babraham Institute researchers have discovered that melanoma cells are drawn to follow the 'trail' of a naturally-occurring molecule in the body, which directs this serious type of skin cancer to spread, according to research published in PLOS Biology.
Using their combined expertise, the researchers discovered that melanoma cells give themselves the 'green light' to move using the molecule – a type of fatty chemical (lipid) called lysophosphatidic acid (LPA). This signal prompts them to travel and spread in the body.
The researchers showed in cancer cell lines and mice that tumour cells start their journey by first breaking down a nearby source of LPA molecules. Once nearby levels of LPA are depleted, the cells then move out of the tumour in search of more. This creates a trail leading to the bloodstream and onto a new site in the body. The lipidomics expertise at the Babraham Institute was essential in determining changes in LPA concentration and identifying the molecular trail.
Unlike other cancers, where cells stick tightly to their neighbours, the structure of melanoma cells means they are primed to spread from the start. So as soon as they have taken the directions given by LPA they start moving. This means the cancer can be difficult to treat because it spreads quickly and aggressively.
The researchers filmed the cells and found that they move at speed, spreading around the body at a pace of a millimetre per day. This speed means a cell can arrive anywhere in the body within a few weeks.
Lead author, Professor Robert Insall, Cancer Research UK scientist at the Beatson Institute for Cancer Research at the University of Glasgow, said: "Our exciting findings show that skin cancer cells create their own 'green light' signal to start spreading, and are lured to travel around the body by a trail of these fatty molecules.
"The next step will be to find how the melanoma cells break down the LPA molecules to see if this sparks ideas for new ways to stop the cancer from spreading. At the moment our research is still in early stages but we hope this could help doctors to make sure this cancer doesn't spread."
Babraham Institute Director and author on the paper, Professor Michael Wakelam said: “This collaborative study demonstrates the importance of basic bioscience in understanding how diseases can develop. The unique lipidomics capability at the Babraham Institute provides a resource for characterising and quantifying lipids such as LPA and thereby makes research such as this possible.”
The rates of people diagnosed with melanoma are five times higher than 40 years ago. Over 13,000 people are diagnosed with melanoma every year in the UK. Each year, around 2,200 people die from the disease.
Professor Nic Jones, Cancer Research UK's chief scientist, said: "Sadly there are few options available for patients whose melanoma has spread, which is especially concerning as this type of cancer has risen rapidly since the 70s. "Research like this is crucial to find effective ways to limit the spread of tumours and increase the chances for more successful treatment of this horrible disease.
"We can all also reduce our risk of the disease by keeping safe in the sun. When the sun is strong it's best to cover up with clothes and spend time in the shade to protect your skin from sunburn and reduce your risk of skin cancer."
Publication reference: Insall et al. (2014). Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal. PLOS Biology.
Louisa Wood, Communications Manager, Babraham Institute
Tel: 01223 496230
Mob: 07833 481170
Emily Head, Cancer Research UK Press Office
Tel: 020 3469 6189
Mob: 07050 264 059
Notes to Editors:
About the Babraham Institute:
The Babraham Institute undertakes world-class life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. Our research focuses on cellular signalling, gene regulation and the impact of epigenetic regulation at different stages of life. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and support healthier ageing. The Institute is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, through an Institute Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities.
The Biotechnology and Biological Sciences Research Council (BBSRC) is the UK funding agency for research in the life sciences. Sponsored by Government, BBSRC annually invests around £450 million in a wide range of research that makes a significant contribution to the quality of life for UK citizens and supports a number of important industrial stakeholders including the agriculture, food, chemical, health and well-being and pharmaceutical sectors. BBSRC carries out its mission by funding internationally competitive research, providing training in the biosciences, fostering opportunities for knowledge transfer and innovation and promoting interaction with the public and other stakeholders on issues of scientific interest in universities, centres and institutes.